Trial Profile
A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Nedaplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Feb 2023 Status changed from recruiting to completed.
- 18 Oct 2020 Results published in the Investigational New Drugs
- 31 May 2020 Results (n=53) assessing safety and efficacy of combination of endostar plus paclitaxel and nedaplatin recurrent or metastatic esophageal squamous cell carcinoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology